Skip TIPS, Try MLPs...
Health Care: Drugs
Vivus (VVUS: NASDAQ)
$12.82 0.00 | 0.00%
02/08/12 - 04:00 PM ET
1.91M / 1.80M
Vol / Avg. Vol:12.87 / 12.82
Open / Prev. Close:12.51 - 12.92
Today's Range:6.00 - 13.18
52 Wk Range:31.49%
Performance YTD:TheStreet Rating:
Portfolios with VVUS
- Portfolio NameUser Type
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Contributor10 Most Shorted Stocks in B...
- ContributorBreakout Stocks Of The Week...
- Contributor5 Stocks Under-$10 Setting ...
- UserPRossmango - Speculative Lo...
- ContributorBarron's Research Reports 8...
- UserRipper
Latest VVUS Headlines from TheStreet
- 8 Stocks Hitting New 52-Week Highs 02.07.12 | 01:02 pm
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- 8 Stocks Rising on Unusual Volume 01.12.12 | 02:01 pm
- J.P. Morgan Biotech Confab Live Chat 01.09.12 | 07:01 pm
- 6 Stocks Rising on Huge Volume 01.09.12 | 01:01 pm
- Biotech 2012 Kickoff Party: Investor Preview 01.04.12 | 11:01 am
- Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa 12.22.11 | 07:12 am
- Market Preview: Staving Off the Grinch 12.21.11 | 09:12 pm
- 27 Hot Drugs Facing FDA Approval in 2012 12.19.11 | 10:12 am
Press Releases for VVUS
- REVIVE Trial Results For Avanafil Published In JSM Demonstrate Significant Improvement In Erectile Function - PR Newswire 01.17.12 | 06:01 am
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation Into Vivus, Inc. - Business Wire 12.23.11 | 08:12 am
- Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits - PR Newswire 04.04.11 | 06:04 am
- VIVUS Files European Marketing Authorization Application For QNEXA® In The Treatment Of Obesity - PR Newswire 12.20.10 | 06:12 am
- VIVUS Submits Briefing Document To FDA, Announces Follow-up Meeting To Discuss QNEXA® - PR Newswire 12.14.10 | 06:12 am
- The Law Office Of Robbins Umeda LLP Announces Investigation Of Vivus, Inc. - Business Wire 11.05.10 | 01:11 pm
Partner Headlines for VVUS
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- Vivus' Obesity Drug Label Modified - Analyst Blog - Zacks 01.12.12 | 10:01 am
- Company News for December 23, 2011 - Corporate Summary - Zacks 12.23.11 | 10:12 am
- The Zacks Analyst Blog Highlights: Yahoo, Vivus, Tibco Software, Micron Technology and Bank of America - Press Releases - Zacks 12.23.11 | 09:12 am
- End-of-Day Market Summary for December 22, 2011 - Benzinga 12.22.11 | 04:12 pm
- Econ Data: The Good, the Bad & the So-So - Analyst Blog - Zacks 12.22.11 | 10:12 am
- Ahead of Wall Street - December 22, 2011 - Ahead of Wall Street - Zacks 12.22.11 | 10:12 am
- Vivus Posts Narrower Loss - Analyst Blog - Zacks 11.08.11 | 10:11 am
- Target Date Set for Vivus Drug - Analyst Blog - Zacks 11.07.11 | 06:11 pm
- Vivus Seeks Obesity Drug Approval - Analyst Blog - Zacks 10.19.11 | 10:10 am
